pyrazines has been researched along with Pituitary ACTH Hypersecretion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asari, Y; Daimon, M; Kageyama, K; Niioka, K; Sugimoto, Y | 1 |
| Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A | 1 |
2 other study(ies) available for pyrazines and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Antigens, Differentiation; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 5; Cyclins; Endopeptidases; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Gene Knockdown Techniques; Indenes; Mice; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Pyrazines; RNA, Messenger; Securin; Ubiquitin Thiolesterase | 2020 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |